Node-Positive Breast Cancer: Which Are the Best Chemotherapy Regimens? | Zendy

Wolfgang Janni | Zendy; Brigitte Rack | Zendy; N. Harbeck | Zendy; Ingo Bauerfeind | Zendy; Harald Sommer | Zendy; Klaus Friese | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Node-Positive Breast Cancer: Which Are the Best Chemotherapy Regimens?

Author(s) -

Wolfgang Janni,

Brigitte Rack,

N. Harbeck,

Ingo Bauerfeind,

Harald Sommer,

Klaus Friese

Publication year - 2008

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000149099

Subject(s) - medicine , breast cancer , oncology , chemotherapy , systemic therapy , targeted therapy , cancer , trastuzumab

Breast cancer-associated mortality has been significantly reduced since the 1990s, mainly because of early diagnosis and systemic therapeutic interventions. All three therapy components - cytostatic therapy, endocrine therapy and targeted antibody therapy - are at present necessary tools for the curative treatment of primary breast cancer. This article reviews the evidence base for the use of various chemotherapy schedules in patients with primary, node-positive breast cancer, including schedules in combination with targeted HER2/neu therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research